A precision-oncology biotech emerging from stealth with a $100 million Series A and an epitope-level targeting approach to antibody-drug conjugates designed to differentiate at the antibody-selection ...

Scientists have discovered that in certain circumstances the same DNA can lead to differential cell surface protein presentation on tumor vs. normal cells. When this occurs unique tumor-specific cell ...

Antibody drug conjugates bring a targeted approach to the treatment of many types of cancer, but there’s still room for improving this class of therapies. This week, two startups revealed how they aim ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s ...

Newly uncloaked Stipple Bio is connecting the dots toward multiple early-stage clinical studies for its lead precision oncology asset, buoyed by a $100 million series A financing round. The “heavily ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. A ...

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE)-- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the close ...

- Series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min CEO Jeff Landau said the $100 ...

For most websites, the homepage represents your brand’s first interaction with your audience on your website. As the catch-all landing page where people will be sent by default, your homepage needs to ...